Novartis Ag (NVSEF) Total Non-Current Liabilities (2009 - 2026)

Novartis Ag has disclosed Total Non-Current Liabilities across 15 years of filings, most recently posting $100.0 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $100.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $100.0 million (changed N/A YoY), and the FY2025 annual result was $37.1 billion, up 26.15% from the prior year.
• Total Non-Current Liabilities came in at $100.0 million for Q1 2026 at Novartis Ag, down from $37.1 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $37.1 billion in Q4 2025 to a low of $100.0 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $29.4 billion (2022), against an average of $26.8 billion.
• Across the five-year window, Total Non-Current Liabilities surged 51.45% in 2022 and declined 15.87% in 2023, its largest moves.
• Novartis Ag's Total Non-Current Liabilities stood at $29.4 billion in 2022, then decreased by 8.75% to $26.8 billion in 2023, then advanced by 9.79% to $29.4 billion in 2024, then rose by 26.15% to $37.1 billion in 2025, then sank by 99.73% to $100.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $100.0 million (Q1 2026), $37.1 billion (Q4 2025), and $30.6 billion (Q2 2025), per Business Quant data.